A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis (NCT06744920)

🧪 Interventions in This Study

• Remibrutinib (Blinded) (DRUG)
• Remibrutinib (Open Label) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (130 Sites)

Showing the first 25 of 130 sites.

• Neuromuscular Research Center — Phoenix, Arizona
• Honor Health Research Institute — Scottsdale, Arizona
• Fullerton Neuro and Headache Ctr — Fullerton, California
• University Of Southern California — Los Angeles, California
• Univ Cali Irvine ALS Neuromuscular — Orange, California
• California Pacific Medical Center — Sacramento, California
• Medstar Washington Hospital Center — Washington D.C., District of Columbia
• SFM Clinical Research LLC — Boca Raton, Florida
• Homestead Assoc In Research Inc — Homestead, Florida
• Neurology Associates PA — Maitland, Florida
• AdventHealth — Orlando, Florida
• Neurological Services of Orlando PA — Orlando, Florida
• University of Chicago Medical Centr — Chicago, Illinois
• Mid Atlantic Epilepsy and Sleep Ctr — Bethesda, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• Michigan State University-Department of Neurology — East Lansing, Michigan
• Dent Neurological Institute — Buffalo, New York
• Univ of Cincinnati Medical Center — Cincinnati, Ohio
• Cleveland Clinic Foundation — Cleveland, Ohio
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
• Houston Methodist Hospital — Houston, Texas
• UT Health Science Center — Houston, Texas
• University of WA Division of Cardio — Seattle, Washington
• Center for Neurological Disorders G — Greenfield, Wisconsin
• Novartis Investigative Site — Rosario, Santa Fe Province

📞 Contact the Study Coordinator

Phone: (888) 669-6682

Email: novartis.email@novartis.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Generalized Myasthenia Gravis

• A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis — Scottsdale, Arizona
• A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis — Scottsdale, Arizona
• Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis — Orange, California
• Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis — Los Angeles, California
• Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis — Phoenix, Arizona
• A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. — Scottsdale, Arizona

Explore by condition: All Generalized Myasthenia Gravis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.